Physician profile
Parag Patil
NPI 1629175989
$167,113.87
in general payments reported to CMS, 2019-2025
7 companies · $150K in 2025
The $150K reported for 2025 was more than what 98% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $27.26 · 2021: $29.91 · 2022: $8,233 · 2023: $2,291 · 2024: $5,417 · 2025: $150K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $157K · Food and Beverage: $1,395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $156,658.32 |
| Food and Beverage | $1,394.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuroone Medical Technologies Corporation | $165,327.94 | 2022-2025 | Onerf Ablation System |
| Medtronic USA, INC. | $657.49 | 2019 | |
| Medtronic, INC. | $590.29 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $214.16 | 2019-2025 | General - Dbs, Vercise |
| Nevro Corp. | $129.32 | 2019-2022 | |
| Globus Medical, INC. | $100.74 | 2025 | Senza |
| Spr Therapeutics, INC | $93.93 | 2025 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Patil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.